What was once revolutionary will become more commonplace. 1980’s, when I first heard Rabbit Polyclonal to Caspase 9 (phospho-Thr125) the words immunoinformatics and epitope-mapping algorithm used. As a young researcher with a background in Fortran programming and an interest in infectious diseases, this new area of research, pioneered by Jay Berzofsky, Hannah Margalit and Charles Delisi involving computer programs that could be used to decipher signals that turned on Risedronic acid (Actonel) the immune system, was one that captured my imagination. To most of my peers, the concept of applyingcomputersto vaccine development was as strange a concept as the global shape of the earth was to early cartographers something that could not yet be fully conceived. At the time, vaccine researchers preferred traditional approaches to mapping T cell epitopes believing that epitopes identified using hands-on peptide-by-peptidein vitroassays were more substantial than epitopes selected byin silicomethods. I was convinced, however, that Jay, Charles and Hannah Risedronic acid (Actonel) were right. I persuaded my mentors at the NIH to support me while I tested the hypothesis that we could predict malaria epitopes. We synthesized the peptides that this AMPHI algorithmipredicted, and I went off to The Gambia to work at the Medical Research Council to measure T cell responses to malaria. Although I had been to Africa Risedronic acid (Actonel) before to work on a measles vaccination campaign as a medical student,iithe trip to MRC Fajara was my first exposure to research in the developing world. I met Hilton Whittle there, – a measles researcher who adored living in West Africa, and he taught me to love it just as much. The research was never published but the love for infectious disease vaccine research (and West Africa) remained, so I left Berzofsky’s lab in 1989 to pursue further training in infectious disease under Gerald Keusch (at New England Medical Center, in 1989). A few years later, a casual conversation with another researcher at the New England Medical Center (Judy Lieberman) prompted me begin simple searches of protein sequences for patterns of amino acids that corresponded to MHC (HLA) binding motifs- using Microsoft Word Find for this purpose an idea that might seem as innovative as any of the inventions my pre-teens came up with- but it was from that point of departure, that I truly set out to discover the immunome. Research in immunomics, by definition, involves risk- the field has never been mainstream. In the early years, it was nearly impossible to get funded, but I was given an opportunity to pursue my dream after winning a starter award from the NIH to use computational immunology and epitope-mapping algorithms (at this point, I was still using Microsoft Word Find) to develop a TB vaccine. I wasn’t aware, at the time, that awards came with indirects and that University appointments usually came with startup funds, so I moved from Boston to Brown University with my training award into an empty lab that had no equipment other than the few desktop computers I had purchased with my own funds. I had to be innovative in expanding my funding base along with the usual method of grant writing, so I paid my first technician at the TB/HIV Research Lab at Brown directly from my own clinical salary. Brilliant Brown students like Gabe Meister and Bill Jesdale joined me, and we sold epitope mapping from our lab bench in order to support further research. My drive for funding led me to establish EpiVax, a biotech company, in order to take advantage of higher SBIR paylines. That Risedronic acid (Actonel) initiative paid off, and EpiVax is now a thriving company with a portfolio of big pharma clients and SBIR research grants. I remain its CEO, charting the company’s course while maintaining an active academic career. My explorations have not been confined to the laboratory in Providence. Becoming an infectious disease specialist in the era of AIDS meant caring for HIV-infected women, a pursuit that led me inside prisons, became a passion and launched an online journal (Infectious Diseases in Corrections Report). Infectious disease research also meant travel for fieldwork – measuring immune response in far-flung regions of the world. My well-worn passport is usually proof that I have pursued this means of discovery – opening doors, in the process, for collaborations with developing world researchers who are interested in immunomics. My students also benefit, traveling with.